Amedisys, Inc.
Amedisys, Inc. (AMED) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
amed · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Amedisys, Inc. (AMED) measures how much investors pay for each dollar of the company's trailing earnings. AMED's current PE ratio of 30.65x is calculated by dividing its stock price of $100.99 by its TTM earnings per share of $3.29. −27.4% discount vs 5Y avg 42.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2005 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%25.3x
MedianQ3 · 75%74.2x
Max
At 30.65x, AMED's current P/E is within its average historical range over the past 15 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Amedisys, Inc.You AMED | $3.3B | 30.65x | -55.1% | $3.29 |
 Astrana Health, Inc. ASTH | $1.9B | 54.15x | -20.6% | $0.46 |
 Axonics, Inc. AXNX | $3.6B | N/A | — | -$0.12 |
 CymaBay Therapeutics, Inc. CBAY | $3.7B | N/A | — | -$0.99 |
 LHC Group, Inc. LHCG | $5.3B | 82.28x | +20.6% | $1.97 |
 MorphoSys AG MOR | $2.9B | N/A | — | -$1.38 |
 Morphic Holding, Inc. MORF | $2.9B | N/A | — | -$3.59 |
Industry Average 2 peers with valid PE | — | 68.21x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | 68.71x | $1.32 | — | |
2023-12-31 FY2023 | — | $-0.30 | — | |
2022-12-31 FY2022 | 22.90x | $3.65 | -9.4% | |
2021-12-31 FY2021 | 25.27x | $6.40 | -51.4% | |
2020-12-31 FY2020 | 52.02x | $5.64 | +23.0% | |
2019-12-31 FY2019 | 42.30x | $3.95 | +31.5% | |
2018-12-31 FY2018 | 32.18x | $3.64 | -45.1% | |
2017-12-31 FY2017 | 58.63x | $0.90 | +54.4% | |
2016-12-31 FY2016 | 37.98x | $1.12 | — | |
2015-12-31 FY2015 | — | $-0.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Amedisys, Inc. (AMED) measures how much investors pay for each dollar of the company's trailing earnings. AMED's current PE ratio of 30.65x is calculated by dividing its stock price of $100.99 by its TTM earnings per share of $3.29.
Frequently asked questions
AMED pe ratio · 6 questionsAMED's current PE ratio is 30.65x as of 2026-06-08, based on a stock price of $100.99 and TTM EPS of $3.29. Data sourced from Financial Modeling Prep via AMED's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Amedisys, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08